⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
Latest News
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
globenewswire.com
GMAB
Endava plc (DAVA) Facing Securities Class Action Amid Delayed Financials, Potential Improper Accounting, CFO On Leave
prnewswire.com
DAVA
CC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in The Chemours Company Securities Lawsuit - Contact Levi & Korsinsky
accessnewswire.com
CC
GIL Shareholder Alert: December 14, 2026 Lead Plaintiff Deadline in Gildan Activewear Inc. Securities Class Action - Contact Levi & Korsinsky
accessnewswire.com
GIL
MRP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Millrose Properties Securities Lawsuit - Contact Levi & Korsinsky
accessnewswire.com
MRP
Lost Money on Qfin Holdings, Inc. (QFIN)? Join Class Action Before November 27, 2026 - Contact Levi & Korsinsky
accessnewswire.com
QFIN
Investors Urged to Contact Levi & Korsinsky for Information Before November 27, 2026 - Fluence Energy, Inc. (FLNC)
accessnewswire.com
FLNC
Lost Money on Innventure, Inc. (INV)? Join Class Action Before October 27, 2026 - Contact Levi & Korsinsky
accessnewswire.com
INV
Compagnie de l'Odet : Financial information for the third quarter of 2026
globenewswire.com
VIV
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
globenewswire.com
NVS